Promising results also for this cohort of HER2-low expressing cancers has gained attention and is predicted to change the treatment regime for breast cancer, adding HER2-low as another category for treatment with targeted drugs (Seban et al. 2023; Zhang et al. 2022). The gene discussed is ERBB2; the disease is breast carcinoma.